These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 1742945)

  • 1. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Berman PW; Gregory TJ; Riddle L; Nakamura GR; Champe MA; Porter JP; Wurm FM; Hershberg RD; Cobb EK; Eichberg JW
    Nature; 1990 Jun; 345(6276):622-5. PubMed ID: 2190095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
    Barrett N; Eder G; Dorner F
    Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive response. Encouraging results in the search for an AIDS vaccine.
    Beardsley T
    Sci Am; 1991 Aug; 265(2):26. PubMed ID: 1862329
    [No Abstract]   [Full Text] [Related]  

  • 6. Human trials of AIDS vaccines: current status and future directions.
    Koff WC; Fauci AS
    AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684
    [No Abstract]   [Full Text] [Related]  

  • 7. Two additional AIDS vaccines approved for clinical trials.
    J Am Osteopath Assoc; 1991 May; 91(5):433. PubMed ID: 2061098
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
    DePalma L
    Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
    Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
    J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research indicates rgp 160 provides long-term immunologic protection. Chimpanzee resists HIV challenge more than two years after vaccination.
    Crit Care Nurse; 1991 Sep; 11(8):1. PubMed ID: 1893756
    [No Abstract]   [Full Text] [Related]  

  • 14. [AIDS--HIV envelope protein improves vaccination response].
    GURTLER L
    Fortschr Med; 1991 Dec; 109(35):10-1. PubMed ID: 1774002
    [No Abstract]   [Full Text] [Related]  

  • 15. Which gp160 vaccine?
    Moore J; Lewis GK; Robinson J
    Nature; 1993 Feb; 361(6412):503. PubMed ID: 7679205
    [No Abstract]   [Full Text] [Related]  

  • 16. Current approaches to vaccination against human immunodeficiency viruses.
    Gluckman JC; Yagello M; Bahraoui E; Girard M
    Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice.
    Shirai A; Klinman DM
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):979-83. PubMed ID: 8280480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for an AIDS vaccine.
    Girard M
    Cancer Detect Prev; 1990; 14(3):411-3. PubMed ID: 2117487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gp160 of commercial HIV western blots is not gp160env. Should criteria for seropositivity be revised?
    Fenouillet E; Blanes N; Gluckman JC
    AIDS; 1991 Jun; 5(6):770. PubMed ID: 1883550
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.